Jillian P. Casale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jillian P. Casale has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Christina Teeter Doligalski
Department of Pharmacy UNC Health Chapel Hill North Carolina USA
2 shared publications A.T. Logan
Pharmacy, Tampa General Hospital, Tampa, FL
1 shared publication- Abdolreza Haririan
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
1 shared publication - Amanda Szczepanik
Department of Pharmacy University of Maryland Medical Center Baltimore Maryland USA
1 shared publication - Catriona Jane Bhagra
Department of Cardiology, Cambridge University and Royal Papworth Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, United Kingdom
1 shared publication Emily Garcia
Department of Pharmacy University of Maryland Medical Center Baltimore Maryland USA
1 shared publication
Latest Publications
- 2 February 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (2)
Outcomes of older Black renal transplant recipients receiving basiliximab induction and early steroid withdrawal
The efficacy and safety of early steroid withdrawal (ESW) in Black renal transplant recipients (RTR) remains uncertain, especially when combined with non‐lymphocyte depleting induction. This study compared patient and graft outcomes of older Black and Non‐Black RTR who received basiliximab induction followed by ESW.Included subjects in this single center, retrospective study were first‐time deceased and living donor RTR aged over 65 years who received basiliximab induction therapy and ESW. Black RTR and Non‐Black deceased donor RTR received an oral prednisone taper starting POD3 which was discontinued by POD21 per protocol.Of 139 patients (55 Black and 84 Non‐Black), the Black patient group included a higher percentage of deceased donors and hepatitis C positive donors, and more frequently underwent renal replacement therapy prior to transplant. One Black and zero Non‐Black RTR experienced graft loss within 3 years (p = 1.0). Patient survival was similar at 1 year (93% vs. 97%, p = .16) and 3 years (91% vs. 96%, p = .17). Rejection‐free survival and biopsy‐proven rejection did not differ at 1 or 3 years. Median eGFR and change in eGFR also did not differ between groups. Black patients were maintained on significantly higher median mycophenolate doses from 6 months post‐transplant to the end of the study period (p = .03 and .048).In older Black RTR, basiliximab induction followed by ESW produced comparable patient, graft, and rejection‐free survival compared to Non‐Black RTR over 3 years post‐transplant.
- 2 February 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (2)
Outcomes of older Black renal transplant recipients receiving basiliximab induction and early steroid withdrawal
The efficacy and safety of early steroid withdrawal (ESW) in Black renal transplant recipients (RTR) remains uncertain, especially when combined with non‐lymphocyte depleting induction. This study compared patient and graft outcomes of older Black and Non‐Black RTR who received basiliximab induction followed by ESW.Included subjects in this single center, retrospective study were first‐time deceased and living donor RTR aged over 65 years who received basiliximab induction therapy and ESW. Black RTR and Non‐Black deceased donor RTR received an oral prednisone taper starting POD3 which was discontinued by POD21 per protocol.Of 139 patients (55 Black and 84 Non‐Black), the Black patient group included a higher percentage of deceased donors and hepatitis C positive donors, and more frequently underwent renal replacement therapy prior to transplant. One Black and zero Non‐Black RTR experienced graft loss within 3 years (p = 1.0). Patient survival was similar at 1 year (93% vs. 97%, p = .16) and 3 years (91% vs. 96%, p = .17). Rejection‐free survival and biopsy‐proven rejection did not differ at 1 or 3 years. Median eGFR and change in eGFR also did not differ between groups. Black patients were maintained on significantly higher median mycophenolate doses from 6 months post‐transplant to the end of the study period (p = .03 and .048).In older Black RTR, basiliximab induction followed by ESW produced comparable patient, graft, and rejection‐free survival compared to Non‐Black RTR over 3 years post‐transplant.
- 26 October 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (3) , e1-e42
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement
- 26 October 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (3) , e1-e42
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement
- 28 August 2016
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 36 (9) , 971-982
Pharmacologic Considerations for Solid Organ Transplant Recipients Who Become Pregnant
Females of childbearing age represent a large population of solid organ transplant recipients. With fertility commonly restored after transplantation, the possibility of pregnancy becomes a reality for many patients. Since the first published report of a successful pregnancy after solid organ transplantation in 1963, the number of pregnancies reported for female organ recipients has continued to increase. Despite this, information on the management of immunosuppression during pregnancy is limited, and a summary of these data is lacking in the literature. In addition to the many pharmacotherapeutic challenges in this unique patient population, physiologic changes in the peripartum period significantly affect the pharmacokinetics and pharmacodynamics of commonly used immunosuppressive agents. These changes, as well as the adverse effects and safety concerns of medications, must all be taken in to consideration to optimize outcomes for both mother and baby. In this review, we provide clinicians caring for female solid organ transplant recipients who wish to become pregnant or who are currently pregnant with a comprehensive review of maternal and fetal risks of pregnancy after transplantation. In addition, pharmacokinetic and pharmacodynamic changes of pregnancy will be discussed, and a summary of data regarding optimal immunosuppression management during pregnancy will be presented.
- 28 August 2016
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 36 (9) , 971-982
Pharmacologic Considerations for Solid Organ Transplant Recipients Who Become Pregnant
Females of childbearing age represent a large population of solid organ transplant recipients. With fertility commonly restored after transplantation, the possibility of pregnancy becomes a reality for many patients. Since the first published report of a successful pregnancy after solid organ transplantation in 1963, the number of pregnancies reported for female organ recipients has continued to increase. Despite this, information on the management of immunosuppression during pregnancy is limited, and a summary of these data is lacking in the literature. In addition to the many pharmacotherapeutic challenges in this unique patient population, physiologic changes in the peripartum period significantly affect the pharmacokinetics and pharmacodynamics of commonly used immunosuppressive agents. These changes, as well as the adverse effects and safety concerns of medications, must all be taken in to consideration to optimize outcomes for both mother and baby. In this review, we provide clinicians caring for female solid organ transplant recipients who wish to become pregnant or who are currently pregnant with a comprehensive review of maternal and fetal risks of pregnancy after transplantation. In addition, pharmacokinetic and pharmacodynamic changes of pregnancy will be discussed, and a summary of data regarding optimal immunosuppression management during pregnancy will be presented.
- Open Access
- 1 April 2016
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 35 (4) , S235
Early Acute Kidney Injury in Lung Transplantation Is Associated with Significant Mortality
- 1 April 2016
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 35 (4) , S235
Open AccessEarly Acute Kidney Injury in Lung Transplantation Is Associated with Significant Mortality